PTTG1 and breast cancer: They found that BC patients with higher levels of securin exhibited significantly poorer overall survival (OS), relapse-free survival (RFS), and distant metastasis-free survival (DMFS) compared to patients with relatively lower levels of securin 38-40, 43, 44, 49, 51, 79-81.